Inline videos. See also:Category: Articles with embedded Videos..

Twin-to-twin transfusion syndrome

From Biocrawler, the free encyclopedia.

Twin-to-twin transfusion syndrome (TTTS, also known as Feto-Fetal Transfusion Syndrome (FFTS) and Twin Oligohydramnios-Polyhydramnios Sequence (TOPS)) is a disorder that can affect identical twin or higher multiple pregnancies where two or more foetuses share a common (monochorionic) placenta.

As a result of sharing a single placenta, the blood supplies of the fetuses can become connected, so that the foetuses essentially shares a single blood supply. Depending on the number, type and direction of the interconnecting blood vessels (anastomoses), blood can be transferred disproportionately from one twin (the "donor") to the other (the "recipient"). The transfusion causes the donor twin to have decreased blood volume, retarding the donor's development and growth, and also decreased urinary output, leading to a lower than normal level of amniotic fluid (becoming oligohydramnios). The blood volume of the recipient is increased, which can strain the donor's heart and eventually lead to heart failure, and also higher than normal urinary output, which can lead to excess amniotic fluid (becoming polyhydramnios).

In early pregnancy (before 26 weeks), TTTS can cause both foetuses to die, or lead to severe disabilities. If TTTS develops after 26 weeks, the babies can usually be delivered and have a greater chance of survival without disabilty.

Other than requiring a monochorionic twin (or higher multiple) pregnancy, the causes of TTTS are not known, and its incidence is believed to be random. It is not hereditary or genetic.

TTTS was first described by a German obstetrician, Friedrich Schatz, in 1875. There are a number of different therapies used to treat TTTS, with varying rates of success. The oldest, most traditional treatment is through serial amniocentesis, which involves periodically draining fluid from the recipient twin in an effort to reduce the pressure of the amniotic fluid. Because serial amniocentesis increases the risk of premature delivery, it has very poor outcomes when performed early in pregnancy, especially before fetal viability. TTTS can also be treated by surgery during pregnancy, using fetoscopy to find the interconnecting blood vessels, and a laser beam to coagulate the blood in these vessels, blocking them. This is called fetoscopic laser ablation, and is only performed in a few hospitals worldwide. Outcomes vary widely from case to case, but as of this writing overall statistics of fetoscopic laser ablation indicate a 75% chance that at least one twin will survive, and a 50 - 60% chance that both will survive. Lastly, some anecdotal evidence suggests that TTTS may be related to nutritional deficiencies in the mother. Some doctors recommend complete bed rest for the mother coupled with massive intakes of protein (generally in the form of "protein shakes" such as Boost or Ensure) as a therapy to try to counteract the syndrome. Theories for why this would be effective vary, but some doctors claim to have seen it help. There are, however, no formal clinical trials indicating that the bed rest / high-protein diet is effective.

Research into TTTS is ongoing and best medical practices change quickly with respect to this condition. For the most up-to-date information, consult with a maternal fetal medicine specialist, and one of the foundations supporting Twin to Twin Transfusion Syndrome research listed below.

TTTS is believed to affect roughly 1 in 1000 pregnancies.

[edit]